Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer.

被引：3
|
作者：
Kikuchi, Y.
Takano, M.
Goto, T.
Kouta, H.
Kikuchi, R.
Kudoh, K.
Kita, T.
Furuya, K.
Umayahara, K.
Takizawa, K.
机构：
[1] Ohki Mem Canc Ctr Women, Tokorozawa, Saitama, Japan
[2] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan
[3] Natl Hosp Org, Nishi Saitama Chuo Hosp, Tokorozawa, Saitama, Japan
[4] Nara Prefectural Nara Hosp, Nara, Japan
[5] Canc Inst Hosp, Ariake, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.5085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5085
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
    Kita, T
    Kikuchi, Y
    Takano, M
    Suzuki, M
    Oowada, M
    Konno, R
    Yamamoto, K
    Inoue, H
    Seto, H
    Yamamoto, T
    Shimizu, K
    GYNECOLOGIC ONCOLOGY, 2004, 92 (03) : 813 - 818
  • [2] PHASE II TRIAL OF PACLITAXEL, CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT OR PERSISTENT CERVICAL CANCER
    Suzuki, K.
    Nagao, S.
    Kaneda, M.
    Sibutani, T.
    Yamamoto, K.
    Jimi, T.
    Yano, H.
    Kitai, M.
    Shiozaki, T.
    Matsuoka, K.
    Sudo, T.
    Yamaguchi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 411 - 411
  • [3] Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer
    Kikuchi, Y., Sr.
    Kouta, H.
    Kikuchi, R.
    Takano, M.
    Kita, T.
    Kudoh, K.
    Aoki, D.
    Sugiyama, T.
    Isonishi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
    Yasunaga, Masafumi
    Yahata, Hideaki
    Okugawa, Kaoru
    Shimokawa, Mototsugu
    Maeda, Yumiko
    Hori, Emiko
    Kodama, Keisuke
    Yagi, Hiroshi
    Ohgami, Tatsuhiro
    Onoyama, Ichiro
    Asanoma, Kazuo
    Kato, Kiyoko
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2022, 61 (05): : 818 - 822
  • [5] Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer
    Wright, Jason D.
    Viviano, Dana
    Powell, Matthew A.
    Gibb, Randall K.
    Mutch, David G.
    Grigsby, Perrv W.
    Rader, Janet S.
    GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 489 - 493
  • [6] A COMPARISON OF ADVERSE OUTCOMES WITH THE USE OF BEVACIZUMAB WITH CISPLATIN/PACLITAXEL OR CARBOPLATIN/PACLITAXEL IN RECURRENT, PERSISTENT OR METASTATIC CERVICAL CANCER
    Kotait, Maryam
    Anzai, Tessa
    Chow, Rosa
    Reade, Clare
    Carlson, Vanessa
    Eiriksson, Lua
    Jimenez, Waldo
    Nguyen, Julie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A75 - A76
  • [7] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    O'Malley, David M.
    Richardson, Debra L.
    Rheaume, Patrick S.
    Salani, Ritu
    Eisenhauer, Eric L.
    McCann, Georgia A.
    Fowler, Jeffrey M.
    Copeland, Larry J.
    Cohn, David E.
    Backes, Floor J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 269 - 272
  • [8] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated, recurrent epithelial ovarian cancer
    Hurt, J.
    Backes, F.
    Rheaume, S.
    Richardson, D.
    Fowler, J.
    Copeland, L.
    Cohn, D.
    Eisenhauer, E.
    Salani, R.
    O'Malley, D.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S47 - S47
  • [9] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    Markman, Maurie
    GYNECOLOGIC ONCOLOGY, 2012, 124 (01) : 171 - 171
  • [10] THE EFFECT OF SINGLE WEEKLY PACLITAXEL IN HEAVILY PRETREATED OVARIAN CANCER PATIENTS AND ITS ANTIANGIOGENIC EFFECTS
    Kikuchi, Yoshihiro
    Kita, Tsunekazu
    Takano, Masashi
    Kudoh, Kazuya
    Saito, Keiko
    Fujii, Kazuyuki
    Sasaki, Naoki
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3535 - 3535
12345